Objective. Radiation synovectomy may be indicated for the treatment of chronic synovitis. A number of factors may affect its current use, including availability, limited evidence for its efficacy compared to intra-articular glucocorticoid, and concerns regarding the potential longterm effects of radiation exposure, particularly in younger patients. Specific chromosome-type abnormalities in peripheral lymphocytes can be useful indicators of whole-body radiation exposure. The frequency of these aberrations has been shown to increase in patients who have had radiation synovectomy using yttrium-90 by up to five times compared to baseline levels. Samarium-153 particulate hydroxyapatite (Sm-153 PHYP) is a new radiopharmaceutical currently on trial which appears to have less extra-articular leakage than yttrium-90 compounds. The aim of this study was to identify any increase in specific chromosome-type abnormalities, using published criteria, in patients following Sm-153 PHYP synovectomy of the knee. The 10 patients (five men, five women) in whom the analyses were performed had a mean age of 47 yr (range 28-70 yr).
Treatments involving different forms of radiation con-
The assumption of the linear non-threshold hypothesis (ICRP) for radiation-induced malignant disease means tinue to be used in a number of non-malignant condithat any exposure, however low, must carry some risk. tions, including skin disease, inflammatory arthritis and This is generally accepted as a prudent stance, even hyperthyroidism. The majority of therapeutic options though empirical evidence of increased cancer rates from have potential adverse effects; risk-benefit ratios must epidemiological studies of low-dosed populations has always be considered. A number of studies have assessed proved elusive [6 ] . In the context of synovectomy, the the effects of low-dose radiation and reassuring results development of new radiopharmaceuticals has been have encouraged its ongoing use [1] . The evidence for aimed at refining the characteristics of the compound the safety of radioactive iodine-131 in the treatment of to maximize the dose maintained within the joint and hyperthyroidism has encouraged its widespread use in thus reduce unwanted exposure of extra-articular tissues. patients over 18 yr old [2] . There is no clear evidence Studies assessing an increased risk of malignancy for an increase in malignancy following radiation synorequire large numbers and long-term follow-up, e.g. the vectomy, although there have been a few individual case lifespan study of Japanese A-bomb survivors [7] . reports [3] [4] [5] .
Information from other methods is often used and chromosomal analysis is a technique that can rapidly is associated with an increase in chromosomal aberra-tions in peripheral lymphocytes. These cytogenetic end comprised filtered minimal essential medium with Earle's salts supplemented with 20% fetal calf serum, 1 m points are also markers for increased cancer risk [8] .
Several factors affect the potential risk of radiation, -glutamine, 10 000 U/ml penicillin, 10 000 mg/ml streptomycin and 10 m 5-bromo-2-deoxyuridine. Cultures including the type and total dose of radiation. Extrapolating information from other circumstances of were harvested in the standard way by hypotonic treatment with 0.075  potassium chloride followed by three whole-body radiation exposure, the most important sites for potential neoplastic change are the lymph nodes and washes in methanol:acetic acid (3:1). The prepared slides were kept for a minimum of 2 days before staining by bone marrow. An ideal radiopharmaceutical should have a relatively short half-life, be primarily a b emitter, the fluorescence plus Giemsa method [19] . remain tightly bound in vivo and have minimal leakage
Cytogenetic analysis from the joint [9, 10] . The high proportion of unwanted Chromosomal analysis was performed on first-division extra-articular leakage of gold-198 from joints, up to cells with a complete chromosome complement (defined one-third of the injected dose [11] , and the significant as the presence of 46 centromeres) by staff of the levels of unwanted c emission, led to the development University College Hospital London cytogenetics unit. of yttrium-90 ( Y-90) compounds [12] . Samarium-153
The criteria for scoring chromosome-type abnormalities particulate hydroxyapatite (Sm-153 PHYP) has a were followed as previously described [20] . Other number of advantages over the Y-90 compounds: the chromatid-type aberrations were also recorded. The half-life of Sm-153 is shorter than that of Y-90 (46.3 number of cells scored varied from patient to patient compared to 64.8 h) and extra-articular leakage of ( Table 1) , but for any one patient the same number was Sm-153 PHYP is significantly lower than that of Y-90 scored for the pre-and post-treatment specimens. compounds [13] . The other relevant characteristics of Sm-153 PHYP also support its use: Sm-153 primarily emits b rays with an average tissue penetration of Results 0.8 mm, >99% of the Sm-153 remaining bound to hydroxyapatite in vivo [14] .
Clinical details (Table 1 ) Chromosome-type aberrations are present in~0.3%
The 10 patients (five men, five women) in whom the (dicentrics 0.1%) of studied metaphases in the normal analyses were performed had a mean age of 47 yr (range population [15] . Their frequency is affected by radiation 28-70 yr). Four of the patients were known to have exposure, a wide number of chemical agents, including rheumatoid arthritis; four had undifferentiated seronegaphenylbutazone [16 ] , methotrexate and azathioprine tive oligoarthritis and two had psoriatic arthritis. The [17], age [15] and smoking [18] . median disease duration was 7 yr (range 2-25 yr).
Chromosome-type aberrations (Fig. 1)

Materials and methods
The number of chromosome-type abnormalities Patients observed was small, with no significant difference in the number of abnormalities before and after treatment. In The analysis was performed on patients recruited in a this sample of 6160 cells, a background level of~3-6 double-blind controlled trial of Sm-153/hydroxyapatite dicentrics would be expected. Analysis showed four radiation synovectomy. The injection procedure was dicentrics, 20 acentric fragments and no acentric rings carried out in the Institute of Nuclear Medicine, or minutes. University College London. The patients were immobilized in the department for 4 h following the procedure Chromatid-type aberrations and advised to rest at home for the subsequent 24 h Chromatid breaks and exchanges were also scored. [13] . The patient study numbers shown in Table 1 refer There was no clear correlation between these abnormalto those in the double-blind trial, E. K. O'Duffy et al., ities and exposure to disease-modifying drugs. in preparation.
Quality analysis Sampling
Coded slides from two patients were analysed by indeBlood samples were taken from each patient in the pendent scorers at the National Radiological Protection month preceding the treatment and between 1 and 3
Board. There was good correlation between chromomonths after they had received intra-articular triamcinosome-type aberration scores from the two groups of lone hexacetonide and Sm-153/hydroxyapatite. Venous observers. blood was collected into preservative-free lithium/heparin tubes and all samples were prepared for culture within 24 h of venesection; during this time, the blood Discussion was kept at room temperature.
There are currently two main methods of assessing Culture chromosomal damage: aberration analysis, as performed in this study, and the identification of micronuclei. Routine whole-blood or buffy coat cultures (0.25 ml in 4 ml medium) were incubated for 48 h at 37°C, with Micronucleus detection has advantages: scoring is quick and inter-observer variability is minimal. The main colcemid (40 mg/ml ) being added at 45 h. The medium Overall, the yields per cell of chromatid aberrations amongst the 10 patients vary by about an order of magnitude. This may well reflect their different antiinflammatory and analgesic drug histories, although the data are too few to conclude or implicate any particular drug combination.
Conclusion
These results offer further evidence for the relative safety of Sm-153 PHYP as a radiopharmaceutical in the treatment of chronic synovitis. Previously published data on extra-articular leakage also support its favourable characteristics when compared with Y-90.
